Quick Answer
HALOZYME THERAPEUTICS, INC. reported Operating Income Loss of $469.01 million for the year ending 2025.
- HALOZYME THERAPEUTICS, INC. showed a decrease of -15.0% in Operating Income Loss from 2024 to 2025.
- This data is from HALOZYME THERAPEUTICS, INC.'s annual report (Form 10-K), filed with the SEC on February 17, 2026.
- XBRL data for this metric is available from 2009 to 2025 (17 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 17 years of available data (2009 to 2025), HALOZYME THERAPEUTICS, INC.'s Operating Income Loss has grown by 902.3%.
- Historical annual values: Fiscal year 2025: $469.01 million | Fiscal year 2024: $551.48 million | Fiscal year 2023: $337.57 million | Fiscal year 2022: $267.53 million | Fiscal year 2021: $275.90 million | Fiscal year 2020: $144.26 million | Fiscal year 2019: -$67.61 million | Fiscal year 2018: -$69.33 million | Fiscal year 2017: $81.00 million | Fiscal year 2016: -$83.21 million | Fiscal year 2015: -$27.45 million | Fiscal year 2014: -$63.04 million | Fiscal year 2013: -$80.43 million | Fiscal year 2012: -$53.63 million | Fiscal year 2011: -$19.84 million | Fiscal year 2010: -$54.26 million | Fiscal year 2009: -$58.46 million.
- Data sourced from SEC EDGAR public filings as of June 22, 2026.
Last verified: